Volume 135, Issue 4, Pages 1176-1184 (October 2008) Randomized, Placebo-Controlled Trial of Pioglitazone in Nondiabetic Subjects With Nonalcoholic Steatohepatitis  Guruprasad P. Aithal, James A. Thomas, Philip V. Kaye, Adam Lawson, Stephen D. Ryder, Ian Spendlove, Andrew S. Austin, Jan G. Freeman, Linda Morgan, Jonathan Webber  Gastroenterology  Volume 135, Issue 4, Pages 1176-1184 (October 2008) DOI: 10.1053/j.gastro.2008.06.047 Copyright © 2008 AGA Institute Terms and Conditions

Figure 1 Changes in hepatic histology in the 2 groups at 12 months of treatment. (Proportion of subjects who had 0 = no change, 1 = increase in a particular histologic feature by one grade, −1 = decrease in particular histologic feature by one grade. Similarly +2, +3, −2 and −3 represent proportion with increase and decrease in histologic features by 2 or 3 grades.) (A) steatosis, (B) hepatocellular injury, (C) lobular inflammation, (D) portal inflammation, (E) Change in Mallory–Denk bodies score, and (F) fibrosis. , Placebo; , pioglitazone. Gastroenterology 2008 135, 1176-1184DOI: (10.1053/j.gastro.2008.06.047) Copyright © 2008 AGA Institute Terms and Conditions